Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
157.77B
Market cap157.77B
Price-Earnings ratio
37.24
Price-Earnings ratio37.24
Dividend yield
6.12%
Dividend yield6.12%
Average volume
34.98M
Average volume34.98M
High today
$28.19
High today$28.19
Low today
$27.44
Low today$27.44
Open price
$28.15
Open price$28.15
Volume
21.54M
Volume21.54M
52 Week high
$29.21
52 Week high$29.21
52 Week low
$23.62
52 Week low$23.62

Stock Snapshot

As of today, Pfizer(PFE) shares are valued at $27.68. The company's market cap stands at 157.77B, with a P/E ratio of 37.24 and a dividend yield of 6.12%.

During the trading session on 2026-10-02, Pfizer(PFE) shares reached a daily high of $28.19 and a low of $27.44. At a current price of $27.68, the stock is +0.9% higher than the low and still -1.8% under the high.

Trading activity shows a volume of 21.54M, compared to an average daily volume of 34.98M.

The stock's 52-week range extends from a low of $23.62 to a high of $29.21.

The stock's 52-week range extends from a low of $23.62 to a high of $29.21.

PFE News

TipRanks 3h
Pfizer’s TACTIVE-U Breast Cancer Combo Trial Reaches Key Milestone

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. (PFE) has updated results from its TACTIVE-U Sub-Study C, a Phase 1b/2 trial...

The Motley Fool 3h
Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

As the global healthcare landscape shifts toward weight-loss treatments and chronic care, investors are weighing two giants. Should you invest in Novo Nordisk A...

Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
TipRanks 4h
Pfizer says LITFULO significantly improved repigmentation in patients

Pfizer (PFE) presented results from two Phase 3 trials evaluating the efficacy and safety of LITFULO as a once-daily oral treatment across a wide range of disea...

Analyst ratings

61%

of 28 ratings
Buy
32.1%
Hold
60.7%
Sell
7.1%

More PFE News

The Motley Fool 11h
Pfizer Is Down 34% Over the Last 5 Years. Here's Why Its 6% Dividend Yield Might Finally Be Worth the Risk.

If you've been looking for high-yield stocks, Pfizer (PFE -1.40%) may have crossed your radar screen. As shares of the pharma giant slipped over the past few ye...

Pfizer Is Down 34% Over the Last 5 Years. Here's Why Its 6% Dividend Yield Might Finally Be Worth the Risk.
The Motley Fool 21h
Kevin Warsh's Inflation Stance Makes These Cheap Dividend Stocks Look a Lot More Attractive

After 100 days at the head of the Federal Reserve, Kevin Warsh gave a speech outlining the economic situation. While employment has been stable, which is positi...

Kevin Warsh's Inflation Stance Makes These Cheap Dividend Stocks Look a Lot More Attractive
Benzinga 1d
Pfizer Says Eczema Drug Shows Significant Skin Clearance

Pfizer Inc. (NYSE:PFE) on Thursday presented detailed Phase 2 results for tilrekimig (PF-07275315) in adults with moderate-to-severe atopic dermatitis. The ong...

Pfizer Says Eczema Drug Shows Significant Skin Clearance
Simply Wall St 1d
Does Pfizer Have A New Growth Driver In Tilrekimig?

Pfizer (NYSE:PFE) reported Phase 2 data for tilrekimig, a trispecific antibody candidate, in moderate to severe atopic dermatitis. The study showed clinically...

Does Pfizer Have A New Growth Driver In Tilrekimig?
TipRanks 1d
Florida sues Pfizer over COVID vaccine marketing

Florida Attorney General James Uthmeier filed a lawsuit against Pfizer (PFE) and its CEO Dr. Albert Bourla. Uthmeier said via X: “Weeks ago we learned Fauci and...

24/7 Wall St. 1d
Treasury Yields Are Above 5%. These 4 Dividend Stocks Still Make the Cut

Investing Treasury Yields Are Above 5%. These 4 Dividend Stocks Still Make the Cut A 5% Treasury yield raises the bar for every dividend stock in a retirement p...

Treasury Yields Are Above 5%. These 4 Dividend Stocks Still Make the Cut
TipRanks 1d
Pfizer says Phase 2 study of tilrekimig met primary endpoint

Pfizer (PFE) presented detailed results from an ongoing Phase 2 study investigating tilrekimig in adults with moderate-to-severe atopic dermatitis. The study me...

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.